Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Ardelyx, Inc. (ARDX)

0.594   0.004 (0.7%) 07-04 17:24
Open: 0.58 Pre. Close: 0.5899
High: 0.6084 Low: 0.575
Volume: 1,777,006 Market Cap: 86(M)
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.61 - 0.61 0.61 - 0.61
Low: 0.57 - 0.57 0.57 - 0.57
Close: 0.59 - 0.59 0.59 - 0.6

Technical analysis

as of: 2022-07-01 4:20:06 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 0.76     One year: 0.88
Support: Support1: 0.49    Support2: 0.4
Resistance: Resistance1: 0.65    Resistance2: 0.75
Pivot: 0.57
Moving Average: MA(5): 0.58     MA(20): 0.59
MA(100): 0.78     MA(250): 1.21
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 55.1     %D(3): 44.9
RSI: RSI(14): 46.7
52-week: High: 8.09  Low: 0.49
Average Vol(K): 3-Month: 3,445 (K)  10-Days: 4,857 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ARDX ] has closed below upper band by 31.2%. Bollinger Bands are 56.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Sun, 03 Jul 2022
Ardelyx to Present at the Jefferies 2022 Healthcare Conference - GuruFocus.com

Fri, 01 Jul 2022
Ardelyx (NASDAQ:ARDX) Rating Increased to Hold at StockNews.com - Defense World

Thu, 30 Jun 2022
Ardelyx secures $20M financial deal on tenapanor potential sale (NASDAQ:ARDX) - Seeking Alpha

Fri, 24 Jun 2022
Ardelyx (NASDAQ:ARDX) Rating Lowered to Sell at StockNews.com - Defense World

Thu, 16 Jun 2022
Should You Buy Ardelyx Inc (ARDX) Stock on Thursday? - InvestorsObserver

Thu, 09 Jun 2022
Ardelyx, Inc. (NASDAQ:ARDX) CEO Michael Raab Sells 103624 Shares - Defense World

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 113 (M)
% Held by Insiders 1.2834e+008 (%)
% Held by Institutions 1.3 (%)
Shares Short 9,760 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.529e+008
EPS Est Next Qtl -0.52
EPS Est This Year -2.21
EPS Est Next Year -2.12
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 528.6
Return on Equity (ttm) -54.9
Qtrly Rev. Growth 1.01e+007
Gross Profit (p.s.) -23.95
Sales Per Share -84.2
EBITDA (p.s.) 2.76667e+006
Qtrly Earnings Growth -1.6
Operating Cash Flow 0 (M)
Levered Free Cash Flow -153 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio -0.1
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 1.4

Stock Dividends

Dividend 0
Forward Dividend 1.154e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.